ELI LILLY & Co: Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis · Ereignisanalyse & Evidenz

BoerseAI

ELI LILLY & Co: Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis · Ereignisanalyse & Evidenz · BoerseAI

Ereignis wird geladen …